| Company Name: |
InvivoChem |
| Tel: |
+1-708-310-1919 +1-13798911105 |
| Email: |
sales@invivochem.cn |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
Prexasertib mesylate manufacturers
|
| | Prexasertib mesylate Basic information |
| Product Name: | Prexasertib mesylate | | Synonyms: | Prexasertib mesylate;5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile mesylate;Prexasertib mesylate (LY-2606368 mesylate);LY2606368 mesylate | | CAS: | 1234015-55-4 | | MF: | C19H23N7O5S | | MW: | 461.5 | | EINECS: | | | Product Categories: | | | Mol File: | 1234015-55-4.mol |  |
| | Prexasertib mesylate Chemical Properties |
| solubility | DMSO:24.0(Max Conc. mg/mL);52.0(Max Conc. mM) |
| | Prexasertib mesylate Usage And Synthesis |
| Uses | Prexasertib Mesylate is a novel CHK1 inhibitor under investigation as a chemopotentiating agent. It causes double-stranded DNA breakage while simultaneously removing the protection of the DNA damage checkpoints. Prexasertib Mesylate is representative of a novel class of drugs for the treatment of cancer and tumor growth inhibition. | | in vivo | Prexasertib mesylate (1-10 mg/kg; SC; twice daily for 3 days, rest 4 days; for three cycles) causes growth inhibition in tumor xenografts[1].
Prexasertib mesylate (15 mg/kg; SC) causes CHK1 inhibition in the blood and the phosphorylation of both H2AX (S139) and RPA2 (S4/S8)[1]. | Animal Model: | Female CD-1 nu-/nu- mice (26-28 g) with Calu-6 cells[1] | | Dosage: | 1, 3.3, or 10 mg/kg | | Administration: | SC; twice daily for 3 days, rest 4 days; for three cycles | | Result: | Caused statistically significant tumor growth inhibition (up to 72.3%).
|
| | IC 50 | Chk1: 0.9 nM (Ki); Chk1: <1 nM (IC50); Chk2: 8 nM (IC50) |
| | Prexasertib mesylate Preparation Products And Raw materials |
|